A5044949041- Ovarian cancer diagnosis and treatment
- Colorectal Cancer Treatments and Studies
- Endometrial and Cervical Cancer Treatments
- Pancreatic and Hepatic Oncology Research
- PI3K/AKT/mTOR signaling in cancer
- Growth Hormone and Insulin-like Growth Factors
- Gastric Cancer Management and Outcomes
- Cervical Cancer and HPV Research
- Cancer Genomics and Diagnostics
- Biochemical and Molecular Research
- Colorectal and Anal Carcinomas
- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Protein Degradation and Inhibitors
- Melanoma and MAPK Pathways
- Cancer Mechanisms and Therapy
- Electrolyte and hormonal disorders
- Genetic factors in colorectal cancer
- Potassium and Related Disorders
- Hepatitis B Virus Studies
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- Hippo pathway signaling and YAP/TAZ
Royal Marsden NHS Foundation Trust
2017-2025
Institute of Cancer Research
2017-2025
Royal Marsden Hospital
2017-2024
Instituto Nacional do Câncer
2012-2021
Hospital do Câncer III
2013-2018
Universidade Federal de Minas Gerais
2010
AT13148 is an oral AGC kinase inhibitor, which potently inhibits ROCK and AKT kinases. In preclinical models, has been shown to have antimetastatic antiproliferative activity.
PURPOSE This study aimed to examine trends in the incidence and mortality rates of endometrial cancer (EC) across ethnic groups Brazil analyze demographic clinicopathological characteristics associated with these trends. METHODS The EC was analyzed from 2010 2015 using data Brazilian Population–Based Cancer Registries (PBCRs), including crude annual percentage changes (APCs). Clinical sociodemographic information 2000 2019 gathered Hospital-Based Registries. Mortality between 2021 were...
BackgroundWe have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised inhibiting signalling the dual m-TORC1/2 inhibitor patients receiving weekly paclitaxel could improve outcomes such patients.Patients and methodsIn dose escalation, (80 mg/m2) was given 6/7 weeks combination two intermittent schedules of vistusertib (dosing starting on day paclitaxel): schedule A, dosed bd for 3 consecutive days per week (3/7 days) B, 2...
The aim of this was to compare the performance Framingham, Systematic Coronary Risk Evaluation (SCORE) and Prospective Cardiovascular Munster (PROCAM) scoring systems in risk assessment HIV-infected patients with no overt vascular disease.A cross-sectional study 220 conducted at outpatient clinic a referral training centre infectious parasitic diseases Belo Horizonte, Brazil. SCORE PROCAM equations were calculated. Patients classified as having low, moderate or high risk, which according...
Scarce data exist about the impact of age in cervical cancer (CC) patients developing world. The objective current study was to examine patterns care and outcome elderly treated a country. Medical records from 2006-2009 at Brazilian National Cancer Institute were reviewed. Patients divided between women 70 years or older younger than years. χ tests used odds ratios calculated. Survival examined using Kaplan-Meier method. Single multivariate Cox proportional hazards modeling used. A total...
Cervical cancer represents the third most commonly diagnosed and fourth cause of death in women worldwide. In palliative scenario, combination paclitaxel cisplatin is widely used. Carboplatin also an active agent cervical cancer, its association with could represent a well-tolerated, less toxic, effective therapeutic option. The objective this study was to evaluate response rate, progression-free survival, overall toxicity carboplatin first line for cancer.A retrospective search database at...
BackgroundThe incidence and clinical significance of electrolyte abnormalities (EAs) in phase I trials are unknown. The objective this study is to evaluate the severity EAs, graded according CTCAE, v4.03, identify variables associated with EAs their prognostic a population.MethodsA retrospective chart review was performed 1088 cases 82 consecutively treated from 2011 2015 at Drug Development Unit Royal Marsden Hospital. Cox regression analysis examine relationship between overall survival...
Abstract Purpose: CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus selectively taken up by α-FR–overexpressing tumors. Patients Methods: A 3+3 dose escalation design was used. During escalation, doses of 1–6 mg/m2 weekly 2–12 every 2 weeks (q2Wk) intravenously were evaluated. with high-grade serous ovarian cancer enrolled in the expansion cohorts. Results: 109 patients enrolled: 42 67 At dose/schedule 12 mg/m2/q2Wk (with without...
2503 Background: ONX-0801 is a first-in-class alpha folate receptor (AFR) targeted thymidylate synthase inhibitor, engineered to differentially accumulate 6000-fold in AFR overexpressing cancer cells. Methods: A 3+3 dose escalation design was used and two IV schedules were explored. Schedule A, weekly dosing (QW) schedule B, once every 2 weeks (Q2W). cycle consisted of 4 treatment stopped after 6 cycles both schedules. An expansion cohort evaluate clinical activity patients with high grade...
Objective: Cervical cancer represents the third most commonly diagnosed and is an important cause of death for women suffering with malignancies. Patients who are refractory or progressed after first-line palliative treatment have a dismal prognosis no second-line chemotherapy considered standard so far. Several agents been investigated in this setting topotecan one characterized. The objective study was to evaluate response rate (RR), progression-free survival (PFS), overall (OS) toxicity...
<h3>Introduction/Background</h3> Bevacizumab, in combination with chemotherapy for frontline therapy, remains a standard-of-care option advanced ovarian cancer. We aimed to evaluate Bevacizumab the first-line treatment of Ovarian Cancer (OC) and correlate it KELIM score (rate elimination Ca 125 constant K) patients high-grade serous cancer (HGSOC) undergoing neoadjuvant (NACT). <h3>Methodology</h3> Retrospective study OC treated at Royal Marsden Hospital (RMH) between February 2012 June...